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Abstract
Background: Antithrombin (AT) is a critical regulator of 
coagulation, and its overall activity is typically measured 
using functional tests. A large number of molecular forms 
of AT have been identified and each individual carries 
multiple molecular proteoforms representing variable 
activities. Conventional functional tests are completely 
blind for these proteoforms. A method that ensures prop-
erly defined measurands for AT is therefore needed. We 
here assess whether mass spectrometry technology, in 
particular multiple reaction monitoring (MRM), is suitable 
for the quantification of AT and the qualitative detection 
of its molecular proteoforms.
Methods: Plasma proteins were denatured, reduced and 
alkylated prior to enzymatic digestion. MRM transitions 
were developed towards tryptic peptides and glycopep-
tides using AT purified from human plasma. For each 
peptide, three transitions were measured, and stable 
isotope-labeled peptides were used for quantitation. Com-
pleteness of digestion was assessed using digestion time 
curves.
Results: MRM transitions were developed for 19 tryptic 
peptides and 4 glycopeptides. Two peptides, FDTISEK 
and FATTFYQHLADSK, were used for quantitation, 
and using a calibration curve of isolated AT in 40  g/L 
human serum albumin, CVs below 3.5% were obtained 
for FDTISEK, whereas CVs below 8% were obtained for 
 FATTFYQHLADSK. Of the 26 important AT mutations, 20 
can be identified using this method, while altered glyco-
sylation profiles can also be detected.
Conclusions: We here show the feasibility of the liquid 
chromatography multiple reaction monitoring mass 
spectrometry (LC-MRM-MS) technique for the quantitation 
of AT and the qualitative analysis of most of its molecular 
proteoforms. Knowing the measurands will enable stand-
ardization of AT tests by providing in-depth information 
on the molecular proteoforms of AT.
Keywords: antithrombin; defined measurands; molecular 
proteoforms; quantitative protein analysis; triple quadru-
pole mass spectrometry.
Introduction
Antithrombin (AT) is a 58-kDa glycoprotein that is typi-
cally present in blood at concentrations of 112–140 mg/L 
[1]. AT is a physiologically critical regulator of coagulation 
by inhibition of thrombin and other coagulation factors. 
The protein contains two functional sites; a heparin-
binding site and a reactive site. When heparin is bound 
to AT, thrombin inactivation is reported to be up to 1000-
fold more efficient [2]. Over 300 genetic defects have been 
described in AT, and hereditary AT deficiencies have been 
associated with venous thromboembolism (VTE) [3]. In the 
general population, the prevalence of AT deficiency varies 
from 1:500 to 1:5000 [4, 5], and in about 0.5% of patients 
with a first VTE, AT deficiency is detected [6]. Because 
thrombin also plays a critical role in arterial thrombosis, 
it was recently suggested that AT deficiencies should also 
be relevant in arterial thrombosis [7]. Although initial lit-
erature does not support this hypothesis [8], recent find-
ings have provided evidence for the role of AT deficiency 
in arterial thrombosis [2, 9, 10]. AT deficiencies may be 
subdivided in two types: quantitative type I deficiencies 
in which the AT concentration is reduced and qualitative 
type II deficiencies in which the AT activity is impaired. 
Type II deficiencies can be further classified based on the 
functional site that is affected, i.e. the reactive site (RS, 
type IIa) or the heparin binding site (HBS, type IIb) or 
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other pleiotropic effects (type IIc). An overview of 26 clini-
cally relevant type II mutations is presented in Table 1.
AT carries four sites of N-glycosylation at aspara-
gines Asn128, Asn167, Asn187 and Asn224. The glycosylation 
profile of AT has been studied quite in-depth using mass 
spectrometric techniques and was shown to be relatively 
homogeneous, with the fully sialylated biantennary 
glycan being by far the most abundant glycan, whereas 
other glycans are present at abundances of only 1–5% [11]. 
Using heparin binding affinity, two distinct proteoforms 
of AT can be identified: α- and β-AT [12]. Although all four 
glycosylation sites are occupied in α-AT, the glycan at one 
of the N-glycosylation sites, N167, is completely missing 
in β-AT [13, 14]. Because of its 2.5-fold increased heparin 
binding affinity, it is speculated that β-AT may be the more 
active form, thus providing the higher anticoagulant activ-
ity (e.g. [15, 16]). Recently, it has been reported that overall 
differential glycosylation caused by type II congenital 
disorders of glycosylation was observed in 27% of cases 
with AT deficiency without genetic defects in the encod-
ing gene [7, 17, 18], thus indicating an important role of AT 
glycosylation for its activity.
Currently, two main types of AT tests are in use; 
activity-based functional tests and antigen-based immu-
noassays [19]. Typically, when AT deficiency is suspected, 
a functional test is performed first. If the functional test 
shows a deficiency, an immunoassay follows to assess the 
type of AT deficiency. However, this strategy requires the 
use of two tests for a diagnosis, does not point towards the 
particular molecular defect and does not determine the 
relative quantities of α-AT over β-AT. The interlaboratory 
precision of the current activity tests is good with CVs of 
4–7% for healthy individuals and 8–12% for patients [20]; 
however, differences in the detection of type II deficien-
cies have been observed between commercially available 
functional tests [2, 21, 22]. Such results may lead to missed 
diagnoses of AT deficiency. Therefore, as was recently 
recognized [7], alternative techniques for the detection 
and quantitation of AT and its deficiencies, which ensure 
a properly defined measurand by taking the molecular 
forms of AT into account, are required.
One promising technique for such an assay is mass 
spectrometry (MS), because bottom-up proteomics strate-
gies have long been recognized as a powerful tool for the 
identification of proteins [23]. The technology is also highly 
suited for the identification of relevant molecular forms in 
which the protein product of a single gene can be found, 
including changes due to genetic variations, alternatively 
spliced RNA transcripts and post-translational modifica-
tions [24, 25]. Quantitative clinical chemistry proteomics 
(qCCP) using MS was recently introduced in the clinical 
chemistry laboratory as a technique that lacks most of the 
drawbacks of immunoassays and allows for multiplex-
ing of tests [26, 27]. Therefore, we believe MS could be an 
excellent technology for the quantitation of AT and the 
detection of its proteoforms – both genetic mutations as 
well as altered glycosylation. Our group recently devel-
oped and provisionally validated an MS-based method 
for the multiplexed quantitation of six apolipoproteins, 
including apolipoprotein E phenotyping using LC coupled 
to multiple reaction monitoring (MRM) MS [28], showing 
the potential for a mass spectrometry based test for abso-
lute protein quantitation, with analytical performance 
specifications meeting clinical requirements.
In this study, we aim to assess the potential of MS 
technology for the quantitation of AT and the qualita-
tive detection of its molecular deficiencies (pathological 
proteoforms). To allow for metrological traceability, the 
proper characterization of the different AT proteoforms 
is necessary as the measurands need to be accurately 
defined. Therefore, four method requirements were aimed 
at to assess as many clinically relevant proteoforms of AT 
variation as possible: (1) absolute quantitation of the AT 
concentration, (2) identification of clinically relevant AT 
mutations, (3) relative quantitation of α- and β-AT and (4) 
identification of altered AT glycosylation profiles. To our 
knowledge, this is the first attempt at a MS-based char-
acterization of most clinically relevant proteoforms of AT.
Materials and methods
Materials
Iodoacetamide, Tris (Trizma preset crystals, pH 8.1), sodium deoxy-
cholate (DOC), CaCl2, EDTA, HCl, cysteine and formic acid were 
obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Tris(2-carboxyethyl)phosphine (TCEP) was from Thermo Scientific 
(Rockford, IL, USA), and ammonia was obtained from MerckMil-
lipore (Amsterdam, The Netherlands). Sequencing-grade modified 
porcine trypsin and chymotrypsin were from Promega (Madison, 
WI, USA), whereas GingisRex was obtained from Genovis AB (Lund, 
Sweden). HPLC-grade methanol was from Biosolve (Valkenswaard, 
The Netherlands). Human serum albumin (HSA) solutions of 40 g/L 
in physiological saline (Albuman®) were from Sanquin (Amster-
dam, The Netherlands). Oasis HLB, MCX and WAX cartridges were 
obtained from Waters (Milford, MA, USA). Synthetic peptides (both 
stable isotope labeled and non-labeled) were obtained from our in-
house peptide synthesis facility and were at least 89.4% pure by 
HPLC. Human-derived AT and β-AT protein standards were obtained 
from J. Amiral and were prepared through affinity chromatography 
on heparin-Sepharose gel by elution with a salt gradient from 0.30 
to 2.00  M NaCl. The protein concentrations were determined with 
Lowry’s method [29].
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Digestion of standard proteins using four proteases
Human-derived AT standard was digested according to the manufac-
turer’s recommendations using trypsin, chymotrypsin or GingisRex. In 
short, 25 μg AT was dissolved in 8 μL MQ water, and added to 40 μL DOC 
(0.40% w/v) and TCEP (2.3 mmol/L) in 100 mmol/L Tris for trypsin diges-
tion, to 40 μL TCEP (2.3 mmol/L) and CaCl2 (10 mmol/L) in 100 mmol/L 
Tris for chymotrypsin digestion and to 40 μL TCEP (2.3 mmol/L), CaCl2 
(5  mmol/L) and EDTA (2  mmol/L) in 100  mmol/L Tris for GingisRex 
digestion. The samples were denatured, and cysteines were reduced 
for 30  min at 56 °C and subsequently alkylated by addition of 20 μL 
4.6 mmol/L iodoacetamide (30 min at RT in the dark). For trypsin diges-
tion, 0.3 μg trypsin in 24 μL resuspension buffer was added, and the 
sample was incubated at 37 °C for 3  h. For chymotrypsin digestion, 
0.3 μg chymotrypsin in 24 μL 1 mmol/L HCl in 100 mmol/L Tris was 
added and the sample was incubated at 25 °C for 20 h. For GingisRex 
digestion, 0.3 μg GingisRex in 24 μL 5 mmol/L CaCl2, 2 mmol/L EDTA 
in 100  mmol/L Tris as well as 1.5 μL of 20  mmol/L freshly prepared 
cysteine were added and the sample was incubated at 37 °C for 20 h. 
Each of the digestions was quenched using 106 μL 0.6% (v/v) formic 
acid, and 150 μL was transferred to an LC-MS vial for analysis.
LC-MS/MS analysis for peptide identification and transi-
tion development
An Agilent 1290 infinity LC system coupled to an Agilent 6495 triple 
quadrupole (QqQ) mass spectrometer (Agilent Technologies, Santa 
Clara, CA, USA) was used for the LC-MRM analysis. The column 
oven temperature was set to 50 °C and the autosampler to 8 °C. A 
10 μL volume of digested sample was injected onto a Zorbax SB-C18 
2.1 × 50  mm analytical column with 1.8 μm particles (Agilent Tech-
nologies), and peptides were separated using a gradient of 5% (v/v) 
methanol in 0.05% formic acid in water (Eluent A) and 95% (v/v) 
methanol in 0.05% formic acid (v/v) in water (Eluent B) at a flow rate 
of 0.2 mL/min. The gradient increased linearly from 0% to 95% elu-
ent B in 12 min, followed by a 4-min wash at 100% eluent B.
For peptide identification, first the MS was operated in full scan 
MS mode with a range of 250–1500 m/z to generate a full MS1 scan of 
the digested samples. Then the instrument was operated in product ion 
scan (PIS) mode to generate fragmentation spectra for m/z that were 
suspected to be AT peptides based on in silico digestion experiments 
using the online tool Peptide Mass (http://web.expasy.org/peptide_
mass/) to identify peptides based on fragmentation pattern. Fragmen-
tation spectra for all tryptic peptides and glycopeptides are shown in 
Supplementary Figure 10. Three transitions were developed per peptide 
and transitions were selected towards fragment ions that were highest 
in abundance and peptide specific. It has to be noted that glycan oxo-
nium ions were used for the transitions of the glycopeptides, which has 
previously been shown to be a suitable strategy [30]. Collision energies 
were optimized for each transition individually and most intense, sta-
ble transitions were selected to be quantifying transitions.
Semiautomated digestion of plasma samples
Samples were prepared on a Bravo liquid handling platform 
equipped with a 96LT disposable tip head (Agilent Technologies) 
and a  temperature-controlled heated lid (Inheco, Martinsried, 
Germany), similarly to our previously reported protocol for the 
digestion of serum samples [28]. To allow for accurate quantitation, 
stable isotope-labeled (SIL) peptides were included for the non-
mutation prone peptides FATTFYQHLADSK and FDTISEK as well 
as the mutation prone peptides ANRPFLVFIR and TSDQIHFFFAK. 
In these peptides, heavy C and N is incorporated in the C-terminal 
lysine or arginine residues, resulting in a mass shift of 8 Da for K and 
10 Da for R residues. Eight microliters of 20-fold diluted plasma was 
added to a 40-μL mixture of DOC (0.40% w/v), TCEP (2.3  mmol/L) 
and 42 fmol of each of the SIL peptides (FATTFYQHLADSK, FDTISEK, 
ANRPFLVFIR and TSDQIHFFFAK) in 100  mmol/L Tris in a 96-well 
plate. The samples were denatured and reduced for 30 min at 56 °C 
under gentle shaking (700 rpm). Then 20 μL 4.6 mmol/L iodoaceta-
mide was added to induce alkylation (30 min at RT in the dark) of 
reduced cysteine residues. Trypsin digestion was performed at 37 °C 
at a 1:35 w/w trypsin-to-protein ratio in 92 μL total volume and gentle 
shaking (700 rpm). During all heated incubations, the sample plate 
was sealed and temperature controlled using the heated lid. After 
3 h, the digestion was quenched by addition of 106 μL 0.6% (v/v) for-
mic acid in 5% (v/v) methanol in water resulting in precipitation of 
the DOC. Next, the sample plate was centrifuged for 10 min at 2000g, 
and 150 μL supernatant was transferred to a clean 96-well plate for 
solid phase extraction (SPE).
Solid phase extraction
To desalt and concentrate AT peptides and glycopeptides, a manual 
SPE step was included. To aid conditioning, equilibration and elu-
tion of solvent from the cartridges, a positive pressure-96 processor 
(Waters) was used. First, the SPE plate was conditioned using 0.1 mL 
MeOH, followed by equilibration with 0.4  mL MQ water. One hun-
dred fifty microliters of the tryptically digested samples was then 
pH adjusted using 25 μL 5% NH3 (aq) in water (pH 12), mixed and 
loaded onto the plate. The plate was washed using 0.5 mL water and 
subsequently eluted using 0.1 mL 80% MeOH in water containing 2% 
formic acid. Eluates were dried using N2 at 37 °C for approximately 2 h 
until dryness. Samples were reconstituted in 50 μL eluent A prior to 
analysis. To evaluate the relative recoveries of endogenous and SIL 
peptides from the SPE, mixtures of 0.15 μM synthetic peptides (n = 6) 
were subjected to SPE, dried and reconstituted. Both the original 
sample and the sample that underwent SPE were analyzed by liquid 
chromatography multiple reaction monitoring mass spectrometry 
(LC-MRM-MS).
LC-MRM-MS analysis
The same LC-MS setup was used for LC-MRM-MS as for the pep-
tide identification, with the exception that the MS was operated in 
dynamic MRM mode. For each peptide, three transitions were meas-
ured in a scheduled MRM list with a 1.0-min retention time window, 
500-ms cycle time and unit resolution for Q1 and Q3.
Data analysis
LC-MS/MS data were processed using Mass Hunter Workstation soft-
ware, version B.07.00 (Agilent Technologies). Signal intensities were 
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obtained from the peak areas, and all transitions (both quantifying 
and qualifying) were evaluated individually. Initial data quality con-
trol was performed by assessing the ion ratios between quantifying 
and qualifying transitions, which were required to be within 15% 
accuracy. The system suitability test was passed for all analyses per-
formed in this study.
System suitability test
To ensure that the LC-MS instrumentation is performing accurately 
during the sample analysis, a system suitability testing (SST) pro-
cedure was designed. In the SST, a sample consisting of eight (non-
labeled) synthetic peptides, each at 0.15 μmol/L in 5% MeOH, was 
prepared. Two microliters of this sample was then analyzed five 
times prior to a test run as well as five times after a test run. Each 
of these five samples was followed by a blank sample to assess 
the carryover. Criteria for accurate performance were pre-defined, 
partially based on Briscoe et al. [31] and CLSI protocol C-62A [32], 
and were as follows: a carryover <1%, <15% difference in instru-
ment counts between the samples before and after and a CV <10% 
between each of the five injections. Furthermore, the ion ratios 
between the quantifying transitions and the qualifying transitions 
should be on target ±15%.
Results
The choice of protease for AT digestion is essential, as 
it determines which peptides should be detected in the 
mass spectrometer, and thus which proteoform charac-
teristics can be identified. Traditionally, trypsin is the 
protease most commonly used for both protein identifi-
cation [33] and protein quantitation. However, the use of 
trypsin would result in a glycopeptide with a short peptide 
backbone for glycosylation site N167: KANK, including one 
missed cleavage due to steric hindrance by the glycan 
moiety [11]. The use of this protease would thus likely 
hamper the application of reverse phase chromatography 
to distinguish α- and β-AT. Therefore, the potential use of 
alternative proteases was evaluated using in silico digests 
of AT with six other proteases commonly used for protein 
identification [33]: LysC, LysN, AspN, ArgC, chymotrypsin 
and GluC. Based on the results, shown in Supplementary 
Table 1, none of the proteases produce readily measurable 
glycopeptides (backbone between 7 and 15 AAs) for all 
four sites of glycosylation. However, peptide backbones 
for site N167 with 13 and 9 amino acids were obtained for 
ArgC and chymotrypsin, respectively. Therefore, it was 
decided to initially evaluate GingisRex, a more specific 
version of ArgC, and chymotrypsin besides trypsin for 
the development of a quantitative method for plasma AT 
characterization.
Comparison of trypsin, chymotrypsin 
and GingisRex for the characterization 
and digestion of AT
To evaluate which of the three proteases is most suitable 
for the quantitation of AT and its proteoform characteris-
tics, we first set out to assess which peptides are observed 
in digests of each of the proteases. Digests of AT stand-
ard were prepared with each of the three proteases, and 
peptides and glycopeptides were identified by first obtain-
ing an MS1 spectrum and then fragmenting the potential 
peptides and glycopeptides to confirm identification. The 
protein sequence coverage thus obtained for each of the 
three proteases is shown in Figure  1. For GingisRex and 
chymotrypsin protein sequence, coverages of 30.1% and 
31.3% were obtained, whereas a sequence coverage of 
53.5% was obtained with trypsin. This is further reflected 
by the number of the 26  most important mutation sites 
that were included in the coverage: 11 for GingisRex, 4 for 
chymotrypsin and 18 for trypsin.
Because the protein quantitation using a bottom-up 
type proteomics approach relies on the stable conver-
sion and consistent enzymatic digestion of protein into 
peptides, a preliminary digestion time course experiment 
was performed with all three proteases. Single samples of 
human-derived AT standard in 40 g/L HSA were digested 
Figure 1: Protein coverage for human plasma-derived AT obtained 
using three different proteases.
To assess the optimal protease, AT was digested using trypsin, 
chymotrypsin and GingisRex, and peptides were identified using MS 
scans followed by product ion scans for confirmation. Parts of the 
sequence highlighted in bold could be identified. Red amino acids 
indicate glycosylated asparagines, and green amino acids indicate 
the presence of a known polymorphism.
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for 0, 1, 3, 6 and 20 h. The results of these experiments are 
shown in Supplementary Figure 1. In general, the peptides 
generated by chymotrypsin are much less stable during 
the digestion, as indicated by the decline in peptide 
recovery for the longer digestion times than the peptides 
from trypsin and GingisRex, which are much more stable. 
However, the abundance of the GingisRex glycopeptide 
KANKSSKLVSANR containing site N167 is very low, and 
only four (larger) peptides are observed from GingisRex, 
of which only one is not containing one of the 26 muta-
tion sites. This limits the absolute quantitation of AT, for 
which at least two of such peptides are desired. Given 
these results, it was decided to further use trypsin as the 
protease of choice during method development.
The LC-MRM-MS method for quantitation of 
AT and its proteoform characteristics from 
plasma
Based on the sequence coverage for AT determined in this 
study, transitions were developed for all tryptic peptides 
and glycopeptides observed in the AT digest and collision 
energies were optimized. A list of the 19 tryptic peptides 
and 4 tryptic glycopeptides monitored is shown in Table 2. 
A chromatogram showing the application of this LC-MRM-
MS method to a tryptic AT standard digest is shown in 
Figure 2. Using this method, 20 out of the 26 most impor-
tant mutations can theoretically be observed (Table 1), 
and all four sites of glycosylation could theoretically be 
monitored. However, the glycopeptide KANK at site N167 
is very short, with limited retention (see Figure 2, small 
signal eluting before 1 min). Therefore, the abundance of 
the signal would likely be around the limit of detection 
when plasma samples were analyzed.
System suitability
To ensure that the LC-MS instrumentation is performing 
accurately during the sample analysis, an SST procedure 
was designed, in which synthetic peptides were analyzed 
five times prior to the sample run and five times upon 
completion of the run. The results of a typical system 
Table 2: Transitions for the peptides and glycopeptides from AT monitored in the LC-MRM-MS method developed.










Rt  Affected by 
mutations?
m/z   CE m/z   CE m/z   CE
33–45   HGSPVDICTAKPR   479.9  732.4   18   593.3   18   572.4   18   5.9  Yes
46–56   DIPMNPMCIYR   705.3  591.3   12   953.4   28   839.4   28   9.4  Yes
72–78   IPEATNR   400.7  590.3   18   461.2   18   687.3   15   4.7  Yes
90–102   FATTFYQHLADSK   510.3  655.8   12   605.4   12   219.1   12   8.0  No
140–146   FDTISEK   420.2  692.3   12   577.3   12   263.1   12   6.1  No
147–157   TSDQIHFFFAK   447.6  796.4   12   620.3   12   576.8   12   9.0  Yes
172–177   LVSANR   330.2  447.2   8   546.3   12   360.2   8   3.3  No
202–208   LQPLDFK   430.7  619.3   12   522.3   20   409.2   20   8.3  No
269–273   ELFYK   350.2  310.2   8   457.2   12   570.3   10   7.0  Yes
274–289   ADGESCSASMMYQEGK   584.2  624.3   12   755.3   15   973.4   15   6.4  Yes
295–307   VAEGTQVLELPFK   715.9  1131.6   25   746.4   25   391.2   25   9.8  No
308–322   GDDITMVLILPKPEK   557.0  748.8   15   635.0   15   288.0   15   10.1  yes
357–364   IEDGFSLK   454.7  794.9   20   665.9   20   215.0   20   7.9  No
383–391   LPGIVAEGR   456.3  701.4   20   531.3   20   268.2   20   7.5  No
392–402   DDLYVSDAFHK   437.2  803.4   15   704.3   15   231.1   15   7.9  No
426–431   SLNPNR   350.7  500.3   8   386.2   12   613.3   8   3.1  Yes
436–445   ANRPFLVFIR   411.6  699.4   10   586.3   10   534.3   10   9.0  Yes
446–457   EVPLNTIIFMGR   695.4  1161.3   20   580.8   20       10.3  No
458–464   VANPCVK   394.2  617.3   8   503.3   12   688.3   12   4.8  Yes
–   TSDQIHFFFAK-SIL   450.1  804.4   12   624.3   12   580.8   12   9.0  –
–   FDTISEK-SIL   424.2  700.3   12   585.3   12   263.1   12   6.1  –
–   FATTFYQHLADSK-SIL   513.0  659.8   12   609.4   12   219.1   12   8.0  –
–   ANRPFLVFIR-SIL   414.8  699.4   10   586.3   10   544.3   10   9.0  –
124–139   GP-LGACNDTLQQLMEVFK   1018.9  366.0   25   274.0   25   204.0   25   10.9  Yes
165–168   GP-KANK   889.4  366.0   25   274.0   25   204.0   25   0.9  No
183–201   GP-SLTFNETYQDISELVYGAK   1096.6  366.0   25   274.0   25   204.0   25   10.8  No
221–225   GP-WVSNK   710.5  366.0   25   274.0   25   204.0   25   4.7  No
SIL peptides are indicated in italics.
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suitability test are shown in Supplementary Figure 2, 
where it can be seen that the retention time is stable, abso-
lute abundances do not deviate more than 10% within 
five samples and no more than 15% between the analy-
ses prior and after the sample measurements, and that 
the carry over is below 1%. The SST was passed every time 
samples were analyzed (including SPE test, optimization 
of the digestion as well as the calibration curves).
AT peptide enrichment and desalting
Because DOC is used as a surfactant and Tris is used as 
the buffer during digestion, which are non-volatile and 
would interfere with MS detection, a sample clean-up 
strategy was optimized. The hydrophilic glycopeptide 
KANK has no retention on an online loading column, and 
therefore off-line SPE was evaluated. At neutral pH, glyco-
peptide KANK is net neutral, as it contains two positively 
charged lysine residues, but also two negatively charged 
sialic acids. Moreover, peptide ANRPFLVFIR contains 
two positively charged arginine residues and is therefore 
positively charged with an estimated pI of 12.1. Because 
of the large variation in chemical properties of the differ-
ent peptides, three stationary phases were considered, 
using four different conditions (see Supplementary Figure 
3F): MCX, WCX and Oasis HLB with retention at both high 
and low pH. First, these conditions were evaluated using 
a tryptic digest of 20 μmol/L purified AT, for which the 
results are shown in Supplementary Figure 3. Glycopep-
tide KANK only showed retention on the MCX material 
and Oasis HLB when high pH conditions were applied. Of 
these two conditions, peptide ANRPFLVFIR was irrevers-
ibly retained on MCX material but could be recovered from 
Oasis HLB using acidic conditions (2% FA) (see Supple-
mentary Figure 3H). Highly similar results were obtained 
when the experiment was repeated using a plasma sample 
(Supplementary Figure 4). However, it has to be noted that 
the ion abundances for glycopeptide KANK were very low, 
potentially due to the lower physiological AT concentra-
tion of ~2 μmol/L, but also due to remaining impurities in 
the sample. Because peptides and glycopeptides started 
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Figure 2: LC-MRM-MS chromatograms AT peptides and glycopeptides in human plasma-derived AT standard and plasma.
The total ion chromatogram is shown in black, whereas the different colors represent the transitions monitored for different peptides, with 
one color representing one peptide. Signals have been annotated with their respective peptide.
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eluting from the Oasis HLB material with 5% methanol, it 
was decided that the optimal SPE procedure is to load the 
sample in 5% NH3(aq), wash with water and elute using 
80% MeOH containing 2% FA. This procedure was further 
used throughout the experiments. The relative recoveries 
of endogenous and SIL peptides were evaluated using a 
mixture of synthetic endogenous and SIL peptides. Recov-
eries of the endogenous and SIL peptides were not signifi-
cantly different (Supplementary Figure 5).
Optimization of the tryptic digestion
It is well known that the tryptic digestion and particularly 
its completion is an important aspect of quantitative clini-
cal chemistry methods for protein quantitation. There-
fore, we assessed the completeness of the digestion using 
a digestion time curve. Human-derived AT standard was 
spiked in 40 g/L HSA and in two randomly selected native 
plasma samples. Samples were prepared in duplo with 
digestion times of 0, 1, 2, 3, 6 and 20 h. Each of the samples 
was analyzed in triplicate. The results of the digestion 
time curve for quantifying peptides FDTISEK and FAT-
TFYQHLADSK for the two plasma samples are shown 
in Figure  3. The digestion curves of the peptides reach 
a plateau by 3 and by 6 h, respectively, whereas there is 
limited degradation of the SIL peptide (less than 10% by 
20 h), indicating these peptides are suitable for accurate 
quantitation. Results of the other peptides and glycopep-
tides monitored for one of the plasma samples are shown 
in Supplementary Figure 6. Clearly, the rate of formation 
of peptides during digestion may vary widely among pep-
tides, as has been observed previously for other proteins 
[34]. However, this does not pose a problem, as these other 
peptides besides FDTISEK and FATTFYQHLADSK are only 
used for relative quantitation.
Calibration of AT test using AT standard 
purified from plasma
To evaluate whether the developed method provides 
precise and more or less accurate results, three calibra-
tion curves were prepared: human-derived AT standard 
Figure 3: Digestion characteristics of quantifying peptides FDTISEK and FATTFYQHLADSK in two plasma samples.
Two plasma samples were digested in duplo, and each sample was analyzed in triplicate for a total of 6 data points. Area counts for the 
endogenous peptides are represented by black crosses and a full line, whereas area counts for the SIL peptides are represented by open 
blue circles and a dotted line.
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as well as human-derived β-AT standard were indi-
vidually spiked in 40 g/L HSA at concentrations of 0, 
0.2, 0.5, 2.0, 5.0 and 20 μmol/L. The calibration curves 
were prepared and analyzed in duplicate. Furthermore, 
four randomly selected plasma samples were included 
in quadruple to preliminarily assess the precision. 
Results of the calibration curve for the human-derived 
AT standard are shown in Supplementary Figure 7. Cali-
bration curves of both AT and β-AT show good linearity, 
but it has to be mentioned that ~10% lower quantities 
are found for the β-AT curve (data not shown), most 
likely indicating that the concentrations of the puri-
fied protein materials as determined by Lowry’s method 
were different. When the concentrations of the four 
plasma samples were calculated based on the average 
calibration curve obtained for AT, CVs below 3.5% were 
obtained for peptide FDTISEK and below 8% for peptide 
FATTFYQHLADSK (Table 3).
To assess the relative concentration of β-AT in a 
sample, the glycopeptide KANK was measured in mixtures 
of β-AT standard in AT standard in 40 g/L HSA at 0%, 5%, 
10%, 20%, 50%, 75% and 100% β-AT at an AT concentra-
tion of 2 μmol/L (Supplementary Figure 8). Unfortunately, 
the area counts of glycopeptide KANK are too low, thus 
indicating that the method is not yet suitable to distin-
guish and quantify β-AT from α-AT.
To further assess whether the calibration curve pre-
pared in HSA is commutable to plasma samples, calibra-
tion curves of AT were prepared in 40 g/L HSA and in two 
randomly selected plasma samples. The resulting calibra-
tion curves are shown in Supplementary Figure 9. Because 
the slopes of the calibration curves in plasma are close 
to 1 relative to the calibration curve in HSA, these results 
indicate that the calibration curve in HSA can be used for 
quantitation of AT in plasma samples.
Discussion
Standardization of any medical test starts with defining 
the measurand(s) at the top of the traceability chain. AT 
measured in an activity-based assay measures overall AT-
activity originating from different molecular proteoforms. 
Novel AT tests that recognize the molecular forms of AT 
are required. MS, which starts to find its way in protein 
clinical chemistry, is a promising technology as it allows 
the identification of specific molecular forms and facili-
tates multiplexed testing. In this study, we assessed the 
potential of LC-MRM-MS for the quantitation of AT and 
its proteoforms. Of our initial four aims to (1) absolutely 
quantify the plasma AT concentration, (2) identify as 
many clinically relevant AT mutations as possible, (3) rela-
tively quantify α- and β-AT and (4) identify altered AT gly-
cosylation profiles, we were successful in three, with the 
exception that we are so far not able to separately quantify 
α- and β-AT. Using SIL peptides as internal standards, we 
were able to quantify AT in four plasma samples with a CV 
below 3.5% for peptide FDTISEK and below 8% for peptide 
FATTFYQHLADSK. It has to be noted that a digestion time 
of 3 h was used to accommodate regular working hours, 
whereas the digestion time courses indicate that peptide 
FATTFYQHLADSK formation is only completed after 6 h. 
This could contribute to the lower precision. So far, the 
trueness of this quantitation remains to be evaluated.
Of the 26 clinically relevant mutations identified, we 
are theoretically able to identify 20 by loss of specific pep-
tides (Table 1). Potentially, this number could be increased 
even further if transitions could be specified for peptides 
LNCQLYR and LNCHLYR, which would be formed upon 
mutation of R161. A strategy in which qualitative analy-
sis of peptides is used to evaluate the mutation status of 
a protein has been shown to be successful for ApoE [28, 
Table 3: Quantitation of AT using LC-MRM-MS in four plasma samples.
FDTISEK FATTFYQHLADSK TSDQIHFFFAK ANRPFLVFIR
Plasma A
 Concentration, μmol/L 1.47 1.72 1.73 1.81
 %CV 2.08 7.63 5.37 1.16
Plasma B
  Concentration, μmol/L 1.24 1.60 1.62 1.51
 %CV 2.14 3.10 2.62 2.28
Plasma C
  Concentration, μmol/L 1.72 2.15 2.28 2.22
 %CV 2.69 4.53 2.61 2.66
Plasma D
  Concentration, μmol/L 1.54 1.81 2.03 1.90
 %CV 3.41 5.67 1.43 2.16
Calibration curves of human-derived AT standard in 40 g/L HSA were prepared in duplicate, and samples were analyzed in quadruplicate.
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35], but the strategy remains to be evaluated for AT. Simi-
larly, we are now able to assess the relative quantity of 
the “typical” sialylated biantennary N-glycans present on 
sites N128, N187 and N224. Reduced quantities of these glyco-
peptides will provide strong indications of altered N-gly-
cosylation profiles.
Unfortunately, the currently developed method is not 
successful in distinguishing α- and β-AT, as the glycopep-
tide KANK, originating from site N167, has no retention on 
the reverse phase LC phase due to its small number of 
amino acids and results in ion counts too low for accu-
rate relative quantitation. Alternative strategies are to 
be considered to specifically target α- and β-AT. One 
such alternative approach could be the derivatization of 
glycosylated peptides, which would alter their chemi-
cal properties. Although glycopeptide derivatization is 
not yet widely applied, several potential strategies have 
been reported [36–38]. Similarly, the use of ion mobility 
MS could be evaluated, as previous preliminary studies 
have shown glycopeptides separation in the ion mobil-
ity phase [39, 40]. Another alternative strategy could be 
the use of immunocapturing in combination with either 
a bottom-up protein quantitation approach, as described 
here, which would allow for the digestion and analysis of 
a concentrated AT sample, or a top-down intact protein 
analysis strategy using high resolution accurate MS. This 
latter strategy was recently applied for the analysis of α-1-
antitrypsin [41].
A two-phased approach was used in the establish-
ment of the LC-MRM-MS test for AT. First, the method 
was developed using the guidance provided by the CLSI 
C62-A guideline [32]. We specifically introduced a system 
suitability check to ensure that the mass spectrometer 
is in optimal condition to perform the measurements. 
Second, lab-developed tests that are intended to be used 
in clinical practice remain to be thoroughly evaluated 
according to, e.g. the cyclical Test Evaluation frame-
work [42]. Under the assumption that the clinical utility 
of AT proteoforms will be demonstrated in the future, 
it remains to be proven that the LC-MRM-MS test for AT 
profiling is robust enough to withstand the rigor required 
in clinical chemistry [43].
Overall, this proof-of-principle study shows the 
potential and challenges of bottom-up proteomics for the 
quantification of plasma AT and for the in-depth charac-
terization of clinically relevant proteoforms. We anticipate 
that knowing the measurands (proteoforms) at the top 
of the metrological traceability chain will enable future 
standardization of AT tests on one hand, as well as recog-
nition of clinically relevant AT proteoforms with specific 
functional defects on the other hand. These technological 
developments will further contribute to precision diag-
nostics to facilitate better patient care.
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